GlassScriptPhysician profile
Christopher R Spinelli
NPI 1205806312
$3,533.43
in general payments reported to CMS, 2019-2025
24 companies · $376 in 2025
The $376 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.91 · 2021: $691 · 2022: $664 · 2023: $833 · 2024: $950 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.26 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,421.05 | 2021-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $161.35 | 2020-2023 | Sogroya, Norditropin |
| Jazz Pharmaceuticals INC. | $114.34 | 2022-2025 | |
| Abbott Laboratories | $111.81 | 2022-2024 | Mitraclip |
| Ucb, INC. | $95.76 | 2023-2024 | Briviact |
| Dexcom, INC. | $85.85 | 2021-2025 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $82.88 | 2022-2024 | Dysport |
| Abbvie INC. | $59.20 | 2021-2024 | |
| Kyowa Kirin, INC. | $43.20 | 2023 | Crysvita |
| Eisai INC. | $40.89 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $35.11 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $35.07 | 2021-2023 | Voxzogo 1.2mg |
| Ns Pharma, INC. | $32.35 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $30.32 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corium, LLC | $26.53 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $24.90 | 2022 | |
| Ascendis Pharma Endocrinology INC | $23.48 | 2024 | |
| Ironshore Pharmaceuticals INC. | $17.19 | 2023 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $17.08 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.43 | 2023 | Triptodur |
| Xeris Pharmaceuticals, INC. | $15.72 | 2023 | Gvoke Hypopen |
| Insulet Corporation | $14.72 | 2023 | Omnipod |
| Eton Pharmaceuticals, INC. | $14.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.98 | 2025 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Spinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.